Results of a phase-I/II randomized, masked, placebo-controlled trial of recombinant human interleukin-11 (rhIL-11) in the treatment of subjects with active rheumatoid arthritis

Table 1 Baseline demographics of patients enrolled in this clinical trial

		Patients given various daily doses of rhIL-11
Characteristics	Patients given placebo	2 × 2.5 μg/kg	1 × 5 μg/kg	2 × 7.5 μg/kg	1 × 15 μg/kg
Number of patients	19	19	17	16	20
Age (years)	49.6	51.8	57.4	49.4	48.7
Sex (%)
Male	32	16	18	44	25
Female	68	84	82	56	75
Race (%)
Black	5	11	0	13	5
Asian	0	0	12	0	0
Other	0	0	6	0	0
Hispanic	11	11	6	13	10
White	84	79	76	75	85
Duration of disease (% of patients)
<2 years	0	5	6	13	15
2-5 years	26	21	24	19	20
>5 years	74	74	71	69	65
Measures of arthritis activity
Swollen-joint count^a	24 ± 11	20 ± 10	21 ± 10	17 ± 10	21 ± 10
Tender-joint count^a	33 ± 13	29 ± 13	32 ± 16	26 ± 12	26 ± 13
Total count^a	57 ± 18	49 ± 22	54 ± 24	43 ± 21	46 ± 22
Physician's assessment^b	5.2	4.7	5.4	4.9	5.0
Patient's assessment^b	4.9	4.4	5.1	5.0	4.8
Patient's pain	4.6	4.1	5.4	5.3	4.8
HAQ^c	1.4	1.3	1.5	1.4	1.4
C-reactive protein	4.8	4.4	7.9	5.2	3.7

^aValues are means ± SD. ^b1 is best and 7 is worst. ^cHAQ = health assessment questionnaire; 0 is best and 3 is worst.

ISSN: 1478-6362